Tina Cheng

8.1k total citations · 1 hit paper
39 papers, 2.3k citations indexed

About

Tina Cheng is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Tina Cheng has authored 39 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 10 papers in Molecular Biology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Tina Cheng's work include Cancer Immunotherapy and Biomarkers (23 papers), CAR-T cell therapy research (16 papers) and Immunotherapy and Immune Responses (7 papers). Tina Cheng is often cited by papers focused on Cancer Immunotherapy and Biomarkers (23 papers), CAR-T cell therapy research (16 papers) and Immunotherapy and Immune Responses (7 papers). Tina Cheng collaborates with scholars based in Canada, United States and India. Tina Cheng's co-authors include Scott North, Christian Kollmannsberger, Daniel Y.C. Heng, Toni K. Choueiri, Brian I. Rini, Jennifer J. Knox, David F. McDermott, Mark Warren, Peter Venner and Bernhard J. Eigl and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Tina Cheng

37 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

2009 1.5k citations Daniel Y.C. Heng, Wanling Xie et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Tina Cheng

Since Specialization

Citations

This map shows the geographic impact of Tina Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tina Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tina Cheng more than expected).

Fields of papers citing papers by Tina Cheng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tina Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tina Cheng. The network helps show where Tina Cheng may publish in the future.

Co-authorship network of co-authors of Tina Cheng

This figure shows the co-authorship network connecting the top 25 collaborators of Tina Cheng. A scholar is included among the top collaborators of Tina Cheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tina Cheng. Tina Cheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Management of Uveal Melanoma: Updated Cancer Care Alberta Clinical Practice Guideline 2023 ·Current Oncology ·Ezekiel Weis, (unknown), Thomas G. Salopek, Tina Cheng, Martin Hyrcza, Xanthoula Kostaras, (unknown), (unknown), John A. McWhae, Geetha Menon, Jose Gerard Monzon, Albert Murtha, John Walker, Claire Temple‐Oberle	8
2	Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma 2023 ·JAMA Network Open ·(unknown), Igor Stukalin, Daniel E. Meyers, (unknown), Daniel Y.C. Heng, Tina Cheng, Jose Gerard Monzon, Vishal Navani	6
3	High-dose chemotherapy with autologous stem-cell transplantation for relapsed metastatic germ cell tumors 2023 ·Canadian Urological Association Journal ·Han‐Bo Zhang, Nimira Alimohamed, Naveen S. Basappa, Tina Cheng, Michael P. Chu, (unknown), D. Scott Ernst, (unknown), Sunita Ghosh, Daniel Yick Chin Heng, (unknown), Scott North, (unknown), Irwindeep Sandhu, Trevor H. Stenson, Douglas A. Stewart, Christopher P. Venner, (unknown), Michael Kolinsky	0
4	Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma 2023 ·Current Oncology ·(unknown), Igor Stukalin, (unknown), (unknown), (unknown), (unknown), Winson Y. Cheung, Daniel Y.C. Heng, Tina Cheng	5
5	Not Waiting to Progress; How the COVID-19 Pandemic Nudged Neoadjuvant Therapy for Stage III Locally Advanced Melanoma Patients 2023 ·Current Oncology ·(unknown), Tina Cheng, Thomas Brenn, J. Gregory McKinnon, Claire Temple‐Oberle	0
6	Stage migration of testicular germ cell tumours in Alberta, Canada, during the COVID-19 pandemic: a retrospective cohort study 2022 ·CMAJ Open ·Richard M. Lee‐Ying, Dylan E. O’Sullivan, (unknown), (unknown), (unknown), (unknown), (unknown), Nimira Alimohamed, Naveen S. Basappa, Tina Cheng, Michael Kolinsky, Safiya Karim, Dean Ruether, Scott North, Steven Yip, Brita Danielson, Daniel Yick Chin Heng, Darren R. Brenner	2
7	Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials 2021 ·European Journal of Cancer ·Chun Loo Gan, Igor Stukalin, Daniel E. Meyers, Shaan Dudani, (unknown), (unknown), (unknown), (unknown), (unknown), J. Connor Wells, Aliyah Pabani, Tina Cheng, Jose Gerard Monzon, Don Morris, Naveen S. Basappa, Sumanta K. Pal, Lori Wood, Frede Donskov, Toni K. Choueiri, Daniel Y.C. Heng	32
8	Real World Outcomes in Patients with Advanced Melanoma Treated in Alberta, Canada: A Time-Era Based Analysis 2021 ·Current Oncology ·(unknown), (unknown), (unknown), Shiying Kong, (unknown), Tina Cheng, Winson Y. Cheung, Jose Gerard Monzon	5
9	Machine learning for prediction of cutaneous adverse events in patients receiving anti–PD-1 immunotherapy 2020 ·Journal of the American Academy of Dermatology ·Ryan T. Lewinson, Daniel E. Meyers, Isabelle A. Vallerand, (unknown), Michelle L. Dean, Tina Cheng, D. Gwyn Bebb, Don Morris	14
10	ILLUMINATE 301: A randomized phase III study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy 2019 ·Annals of Oncology ·Marcus O. Butler, Caroline Robert, Sylvie Négrier, (unknown), John Walker, Ivana Krajsová, Victoria Atkinson, Johan Hansson, Ellen Kapiteijn, Carmen Loquai, Heather M. Shaw, Tina Cheng, Sandrine Mansard, Jean‐Jacques Grob, Massimo Guidoboni, Minal Mehta, Paolo A. Ascierto, Adi Diab	2
11	Utilization of real-world data to assess the effectiveness of immune checkpoint inhibitors (ICIs) in elderly patients with metastatic melanoma 2019 ·Annals of Oncology ·D. Scott Ernst, Hannah McConkey, (unknown), Marcus O. Butler, Teresa M. Petrella, Tara Baetz, (unknown), Xin Song, Tina Cheng, Michael Smylie, (unknown), Catalin Mihalcioiu, Femida Gwadry‐Sridhar	2
12	Aplastic anemia secondary to nivolumab and ipilimumab in a patient with metastatic melanoma: a case report 2018 ·Experimental Hematology and Oncology ·Daniel E. Meyers, William F. Hill, (unknown), Víctor H. Jiménez‐Zepeda, Tina Cheng, Nancy Nixon	25
13	Management of Uveal Melanoma: A Consensus-Based Provincial Clinical Practice Guideline 2016 ·Current Oncology ·Ezekiel Weis, Thomas G. Salopek, J. Gregory McKinnon, Monica Larocque, Claire Temple‐Oberle, Tina Cheng, John A. McWhae, Ron S. Sloboda, Melissa Shea‐Budgell	46
14	Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC) 2016 ·Investigational New Drugs ·Sunil Parimi, Misha Eliasziw, Scott North, Marc Trudeau, Eric Winquist, Kim N., Dean Ruether, Tina Cheng, Bernhard J. Eigl	3
15	The impact of clinical response to anti-CTLA4 treatment on overall survival (OS) in metastatic melanoma (MM). 2014 ·Journal of Clinical Oncology ·Xiaolan Feng, Michael Smylie, Tina Cheng, Jose Gerard Monzon, Richard M. Lee‐Ying	1
16	A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment 2013 ·Canadian Urological Association Journal ·Mark Warren, Peter Venner, Scott North, Tina Cheng, (unknown), Sunita Ghosh, Allison A. Venner, Daygen L. Finch	20
17	Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study 2011 ·Annals of Oncology ·Karin Oechsle, Friedemann Honecker, Tina Cheng, Frank Mayer, Piotr Czaykowski, Eric Winquist, Lori Wood, Martin Fenner, (unknown), J.T. Hartmann, K.N. Chi, Carsten Bokemeyer, Christian Kollmannsberger	72
18	Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study breakdown → 2009 ·Journal of Clinical Oncology ·Daniel Y.C. Heng, Wanling Xie, Meredith M. Regan, Mark Warren, Ali Golshayan, (unknown), Bernhard J. Eigl, Joseph D. Ruether, Tina Cheng, Scott North, Peter Venner, Jennifer J. Knox, Kim N., Christian Kollmannsberger, David F. McDermott, William Oh, Michael B. Atkins, Ronald M. Bukowski, Brian I. Rini, Toni K. Choueiri	1525
19	The Canadian Uro‐Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone‐refractory prostate cancer progressing after mitoxantrone/prednisone 2008 ·British Journal of Urology ·Fred Saad, Dean Ruether, Scott Ernst, Scott North, Tina Cheng, Paul Perrotte, Pierre I. Karakiewicz, Eric Winquist	9
20	High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma 2003 ·Bone Marrow Transplantation ·Tina Cheng, Peter Forsyth, A Chaudhry, Don Morris, Stefan Glück, J A Russell, Douglas A. Stewart	100

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact